<p class=”” data-start=”182″ data-end=”722″>Gefitinib is an oral medication used primarily in the treatment of non-small cell lung cancer (NSCLC), especially in patients whose tumors have specific mutations in the epidermal growth factor receptor (EGFR) gene. As a targeted therapy, Gefitinib works by inhibiting the tyrosine kinase enzyme, which plays a key role in cancer cell growth and survival. This makes it particularly effective for patients who have tested positive for EGFR mutations, often leading to improved progression-free survival compared to traditional chemotherapy.</p>
<p class=”” data-start=”724″ data-end=”932″>Gefitinib is typically prescribed as a once-daily oral tablet, offering convenience and better tolerability for patients. Its side effects are generally manageable and may include diarrhea, rash, and fatigue.</p>
<p class=”” data-start=”934″ data-end=”1398″>India has emerged as a significant hub for the production of high-quality generic oncology medications. Many pharmaceutical companies specialize in manufacturing targeted cancer therapies, making them accessible and affordable. A leading <strong data-start=”1172″ data-end=”1214″>Gefitinib tablet manufacturer in India plays a crucial role in supplying this life-saving medication not only to the domestic market but also to international healthcare systems in need of cost-effective cancer treatments.</p>
<p class=”” data-start=”1400″ data-end=”1534″>With ongoing research and innovation, Gefitinib continues to be a vital tool in the evolving landscape of personalized cancer therapy.</p>